Bryant Mahaffey, MD
Psychiatry · Decatur, ALNPI 1891014742
Payments from drug & device makers
Across 200 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$648
- Sunovion Pharmaceuticals Inc.$550
- Alkermes, Inc.$342
- Teva Pharmaceuticals USA, Inc.$280
- Otsuka America Pharmaceutical, Inc.$231
- Vanda Pharmaceuticals Inc.$209
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,459100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $648 |
| Sunovion Pharmaceuticals Inc. | 43 | $550 |
| Alkermes, Inc. | 18 | $342 |
| Teva Pharmaceuticals USA, Inc. | 17 | $280 |
| Otsuka America Pharmaceutical, Inc. | 15 | $231 |
| Vanda Pharmaceuticals Inc. | 9 | $209 |
| Neurocrine Biosciences, Inc. | 12 | $199 |
| Johnson & Johnson | 8 | $143 |
| Lundbeck LLC | 6 | $105 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $102 |
| Corium, LLC | 6 | $100 |
| Bausch Health US, LLC | 6 | $96 |
| Merck | 5 | $93 |
| Almatica Pharma LLC | 3 | $59 |
| Adlon Therapeutics L.p. | 4 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $52 |
| Avanir Pharmaceuticals, Inc. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Indivior Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Neos Therapeutics, LP | 1 | $18 |
| Brainsway USA Inc | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $14 |
How this compares
$3,459 in reported general payments places this provider in the 80th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $105,254 |
| AustedoDeutetrabenazine | 15 | $96,254 |
| VraylarCariprazine Hcl | 49 | $85,278 |
| RexultiBrexpiprazole | 13 | $23,795 |
| BelsomraSuvorexant | 49 | $22,425 |
| Lurasidone Hcl | 59 | $12,650 |
| TrintellixVortioxetine Hydrobromide | 14 | $11,774 |
| Paliperidone ErPaliperidone | 36 | $10,945 |
| Aripiprazole | 170 | $6,286 |
| Duloxetine Hcl | 182 | $6,105 |
| Trazodone Hcl | 217 | $5,153 |
| QuviviqDaridorexant Hcl | 11 | $5,087 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 105 | $4,636 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 89 | $4,102 |
| Ziprasidone Hcl | 46 | $3,888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $199 | $105,25412 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $280 | $96,25415 claims |
| AbbVieVraylar | $648 | $85,27849 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $231 | $23,79513 claims |
| MerckBelsomra | $93 | $22,42549 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $37 | $11,77414 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $29 | $5,08711 claims |
| Almatica Pharma LLCSertraline Hcl | $59 | $1,439156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Decatur
- Yelena ChistyakovaDecatur$9K
- Matthew MacalusoBirmingham$2.8M
- Richard SheltonBirmingham$2.4M
- Michael FalolaTrussville$2.2M
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Lori DavisTuscaloosa$515K
- Scariya KumaramangalamHuntsville$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.